Incidence Measures for Schizophrenia among Commercial Health Insurance and Medicaid Enrollees

Abstract

ABSTRACTObjectiveTo examine and compare the prevalence, incidence, and specificity and positive predictive value of incidence measures in a national commercial insurance database and a state Medicaid database, for different age groups over the life span.MethodsThis cross-sectional study examined the annual prevalence of schizophrenia in 2019 in two databases: a) MarketScan, a United States national commercial insurance database (N= 16,365,997), and b) New York State Medicaid program (N= 4,414,153). A subset of these individuals with 10 years of continuous insurance prior to 2019 (2009-2018) was used to assess incidence and to create a reference standard for incidence measure testing, including positive predictive value and specificity, by age group. Continuous enrollment was required for all years of study (45-day gap allowance per year, and one or more health care services annually to ensure opportunity to be diagnosed).ResultsThe prevalence of schizophrenia in 2019 was 0.13% in MarketScan, and 2.13% in Medicaid. Prevalence was highest in MarketScan among individuals aged 21-25 years. In contrast, prevalence in Medicaid increased over the lifespan, with the peak among those 56-60 years of age. The incidence of new-onset schizophrenia in 2019 was 0.07% in MarketScan and 0.19% in Medicaid and peaked in young adulthood (26-30 years of age) in both databases (0.16% and 0.40%, respectively). Positive predictive value (PPV) for the incidence measures was higher for women than men and increased with longer lookback periods prior to the first schizophrenia diagnosis in 2019. Using a one-year lookback period, the PPV for those ≤35 years of age was 79% in MarketScan and 51% in Medicaid; a ≥95% PPV was achieved with a two-year lookback in MarketScan, and a seven-year lookback period in Medicaid. PPVs were also higher in younger age groups; in Medicaid a two-year lookback period yielded a PPV of 68% for those ≤35 years, but was 94% for those ≤20 years. Specificity was high even for the total population with one year of observation prior to the first schizophrenia diagnosis in 2019, and was higher in Medicaid (92%) than in MarketScan (80%), increasing further with longer lookback periods in both databases.ConclusionsThe prevalence of schizophrenia is over 10-fold higher, and the incidence two-fold higher, in the New York State Medicaid population compared to the MarketScan national commercial insurance database. Within each database, prevalence and incidence varied by sex, age, and duration of insurance. Yet despite these differences, accurate measures of incidence of new-onset schizophrenia could be constructed with high specificity and positive predictive values.